ライフサイエンスコーパス: releasate

1 fected by soluble components of the platelet releasate.

2 ving fibrin, human fibroblasts, and platelet releasate.

3 ost abundant proteins contained in the BMCMC releasates.

4 onfocal imaging, and measurement of platelet releasates.

5 mography demonstrated free PAI-1 in cellular releasates.

6 e report the presence of proSAAS peptides in releasates.

7 This releasate activates other platelets, promotes wound repa

8 peptide mixtures, including neuronal tissue releasate and protein tryptic digests.

9 Observed SCN releasates are peptide rich and demonstrate the co-relea

10 t tryptase, were identified in the mast cell releasates as the likely culprits that digest these cyto

11 on exposure to activated platelets or their releasates, as judged by immunoblotting for phospho-amin

12 -embedded monolith to condition neuropeptide releasates collected from several Aplysia neurons cultur

13 omatography indicated that staphylocidal PLT releasates contained PMPs and PKs.

14 analyses and immunoassays of human platelet releasates coupled with angiogenesis assays to search fo

15 MC releasate elevated ICAM-1 (intercellular adhesion molecu

16 mast cells produced substantially different releasates following IgE-mediated activation.

17 that treating megakaryocytes (MKs) with the releasate from activated platelets increased proplatelet

18 Similar to recombinant CXCL4, releasate from human platelets also reduced CD163 expres

19 lated secretion of VEGF and a pro-angiogenic releasate from platelets.

20 The releasate from these platelets contained decreased proan

21 slices demonstrates their ability to collect releasates from a variety of neuronal tissues.

22 dition to prostanoids such as thromboxane A2 Releasates from activated platelets caused cell migratio

23 Because platelet releasates from TSP-1 null mice contain active TGF-beta1

24 Platelet releasates generated by activation with ADP promoted mig

25 data indicate that Vn is present in platelet releasates in two molecular weight (M(r) forms.

26 Conversely, TXA(2)-stimulated platelet releasate inhibited migration and formation of capillary

27 Additionally, the content of SCN releasate is stimulation specific.

28 ion of the retinohypothalamic tract, produce releasate mass spectra that are notably different from t

29 We show that platelets, but not platelet releasate, modulate the migration and intercellular adhe

30 also could be generated by beta-tryptase in releasates of activated skin mast cells.

31 o define the proteome contained in mast cell releasates on activation to better understand the factor

32 purified protein complex or in the platelet releasates or sera of mice engineered to contain an LAP

33 ved either fibrin alone, fibrin and platelet releasate, or fibrin and fibroblasts.

34 merases in the activation of LLC in platelet releasates (PR) and recombinant LLC.

35 n trypsin inhibitor, when added to mast cell releasates, prevented the degradation of exogenously add

36 und that different agonists evoked different releasate profiles, with aspirin having a general modera

37 the mast cell protease content can shape its releasate proteome.

38 e tissue mast cells, respectively, and their releasate proteomes were analyzed by mass spectrometry.

39 m, DBP-depleted serum, or activated platelet releasate provides a required factor and permits DBP to

40 nished 95% and 70% of the effect of platelet releasate, respectively, suggesting CCL5 derived from pl

41 Fractionation of activated platelet releasate revealed that the additional factor possessed

42 have been characterized, including platelet releasates (the 'secretome'), alpha and dense granules,

43 igated the effect of aspirin on the platelet releasate using mass spectrometry and found that differe

44 In some wounds, platelet releasate was added to the fibrin clot.

45 ured human fibroblasts, fibrin, and platelet releasate were 14% filled with granulation tissue compar

46 sma and total and size-fractionated platelet releasates were compared (1) immunologically using three

47 ld reproduce the effect of serum or platelet releasate, whereas Abs to TSP-1 could block these effect

48 y sustained accumulation of Abeta(42) in the releasate, which was blocked by the group II mGluR antag

49 by Western blotting of platelet lysates and releasates with anti-FV antibodies.